Post-marketing analysis shows improved bowel movements and safety in patients with chronic idiopathic constipation, indicating efficacy of vibrating capsules.
Introduction: Pharmacological therapies for chronic idiopathic constipation (CIC) are useful, but many patients report dissatisfaction from a lack of efficacy and occurrence of adverse events. The vibrating capsule (VC) is an FDA approved non-pharmacologic, treatment for CIC. However, its long-term usefulness in a community setting is unknown. The goal of this study was to assess the long-term efficacy and safety of vibrating capsule treatment in a real-world community setting. Methods: We conducted a post-marketing analysis of CIC patients prescribed VC who completed at least 3 or 6 months of treatment. The clinical utility was assessed via patient reported symptoms in an electronic stool diary. Safety data was also collected. Results: 1722 patients were prescribed VC, and 491 and 298 took the VC and kept stool diaries for 3 and 6 months respectively. Approximately 46% of patients were >55 years of age and 85% were women. Compared to baseline, complete spontaneous bowel movement (CSBM) rates increased significantly throughout the 3 and 6 -month periods (average increase of >1 CSBM per week; P< 0.0001). Mean stool consistency (Bristol Stool Form Scale) improved from 2.9 (baseline) to 4.1 during treatment (P<0.0001), mean straining effort (1-4) decreased from 2.9 to 1.6 (P<0.0001), and toileting time also significantly decreased (P<0.0001). Safety analysis revealed that 4.6% of patients reported feeling a sensation of vibration, 1.8% reported abdominal pain and 0.64% reported diarrhea. Conclusions: In a community setting, the VC appears both effective and safe for long term treatment of chronic constipation with diarrhea being notably uncommon.
No takes yet. Share an insight, caveat, or question.
Brenner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: